Form 4: Vivo Opportunity Acquires InMed Pharmaceuticals Shares

Vivo Opportunity, LLC and its affiliated entities report acquiring a significant number of InMed Pharmaceuticals Inc. common shares between June 30 and July 2, 2026.

Summary

• Vivo Opportunity, LLC, along with its related entities Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity Cayman Fund, L.P., and Vivo Opportunity Cayman, LLC, have reported the acquisition of InMed Pharmaceuticals Inc. (INM) common shares.
• Transactions occurred between June 30, 2026, and July 2, 2026.
• The acquisitions involved a total of 77,546 shares across multiple transactions.
• The weighted average purchase price for shares acquired on June 30, 2026, was $1.54.
• The weighted average purchase price for shares acquired on July 1, 2026, was $1.55.
• The weighted average purchase price for shares acquired on July 2, 2026, was $1.55.
• Following these transactions, Vivo Opportunity Fund Holdings, L.P. beneficially owns 724,395 shares, and Vivo Opportunity Cayman Fund, L.P. beneficially owns 73,135 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing due to the significant share accumulation by a known investor and director, suggesting confidence, but lacks specific company performance data to warrant a higher score.

Positives

• Significant acquisition of InMed Pharmaceuticals Inc. shares by a substantial investor, Vivo Opportunity, LLC, indicating confidence in the company.
• Multiple transactions suggest a strategic accumulation of shares rather than a single large block purchase.
• The reporting entities are identified as 10% owners and directors, suggesting a strategic interest and potential influence.

Negatives

• The filing does not provide specific financial performance data for InMed Pharmaceuticals Inc., making it difficult to assess the underlying value driving the investment.
• The nature of the acquisition (open market purchases) does not reveal any specific strategic partnerships or insider information.

Risks

• The filing does not explicitly mention any risks associated with these transactions.
• Potential for increased volatility in InMed Pharmaceuticals Inc. stock due to the significant share accumulation by Vivo Opportunity.

Future Outlook

This filing is a statement of changes in beneficial ownership and does not contain forward-looking statements or guidance regarding InMed Pharmaceuticals Inc.'s future performance.

Management Comments

• Vivo Opportunity, LLC disclaims beneficial ownership over securities held by Vivo Opportunity Fund Holdings, L.P. except to the extent of its pecuniary interest.
• Vivo Opportunity Cayman, LLC disclaims beneficial ownership over securities held by Vivo Opportunity Cayman Fund, L.P. except to the extent of its pecuniary interest.
• The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price upon request.

Industry Context

StockSavvy.ai notes that significant share acquisitions by entities identified as 10% owners and directors often signal a belief in the company's future prospects or an intention to influence corporate strategy within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders may view the increased stake by Vivo Opportunity as a positive signal of confidence, potentially influencing share price.
• Management of InMed Pharmaceuticals Inc. may face increased scrutiny or strategic input from Vivo Opportunity due to their significant ownership and director status.

Next Steps

• Continued monitoring of Vivo Opportunity's beneficial ownership in InMed Pharmaceuticals Inc.
• Further analysis of InMed Pharmaceuticals Inc.'s operational and financial performance to understand the strategic rationale behind these acquisitions.

Key Dates

Recommendation

The filing indicates a significant investment by a known entity, suggesting potential upside. However, without InMed Pharmaceuticals Inc.'s own financial performance data or strategic updates, a 'hold' recommendation is prudent, allowing for further information to be gathered before making a stronger conviction decision.

Keywords

InMed Pharmaceuticals, INM, Vivo Opportunity, Form 4, SEC Filing, Beneficial Ownership, Stock Acquisition, Insider Trading, 10% Owner, Director